FDA Expands Safety Signal Assessment With Mechanism-Based System
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will work with MolecularHealth Inc. to adapt the company’s software system, which combines molecular data with clinical data, to allow mechanism-based assessment of side effects.